Literature DB >> 14551151

Adiponectin and metabolic syndrome.

Yuji Matsuzawa1, Tohru Funahashi, Shinji Kihara, Iichiro Shimomura.   

Abstract

In this review article, the crucial roles of adipocytes in the development of so-called metabolic syndrome and vascular disease are reviewed, focusing on adipocyte-derived bioactive substances, adipocytokines. Recent progress in adipocyte biology shows that adipocytes are not merely energy-storing cells but that they secrete a variety of hormones cytokines, growth factors, and other bioactive substances. To search for novel adipocytokines by the large-scale random sequence analysis of expressed genes in adipocytes, we identified an adipose-specific collagen-like molecule, adiponectin. This novel adipocytokine has plural biofunctions, such as antidiabetic, antiatherosclerotic, and antiinflammatory functions. Adiponectin plasma levels decrease with the accumulation of visceral adipose tissue. In this review, we discuss the link of adiponectin to visceral adiposity, insulin resistance, and vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551151     DOI: 10.1161/01.ATV.0000099786.99623.EF

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  252 in total

1.  Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women.

Authors:  George A King; Sarah E Deemer; Dixie L Thompson
Journal:  Acta Diabetol       Date:  2010-05-08       Impact factor: 4.280

Review 2.  Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?

Authors:  Dick C Chan; Jing Pang; Gerald F Watts
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

Review 3.  Adipokines as novel biomarkers and regulators of the metabolic syndrome.

Authors:  Yingfeng Deng; Philipp E Scherer
Journal:  Ann N Y Acad Sci       Date:  2010-11       Impact factor: 5.691

4.  Metabolic syndrome in Tunisian bipolar I patients.

Authors:  A Ezzaher; Mouhamed D Haj; A Mechri; F Neffati; W Douki; L Gaha; M F Najjar
Journal:  Afr Health Sci       Date:  2011-09       Impact factor: 0.927

Review 5.  Nitric oxide synthases in the pathogenesis of cardiovascular disease: lessons from genetically modified mice.

Authors:  Hiroaki Shimokawa; Masato Tsutsui
Journal:  Pflugers Arch       Date:  2010-02-24       Impact factor: 3.657

6.  Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets.

Authors:  N Viguerie; H Vidal; P Arner; C Holst; C Verdich; S Avizou; A Astrup; W H M Saris; I A Macdonald; E Klimcakova; K Clément; A Martinez; J Hoffstedt; T I A Sørensen; D Langin
Journal:  Diabetologia       Date:  2004-12-29       Impact factor: 10.122

Review 7.  Adipocytokines: emerging therapeutic targets.

Authors:  Yuji Matsuzawa
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

8.  Regulating adiponectin: of flax and flux.

Authors:  A M Sharma; M A Tarnopolsky
Journal:  Diabetologia       Date:  2005-06       Impact factor: 10.122

9.  MicroRNA and 3T3-L1 pre-adipocyte differentiation.

Authors:  Kazuaki Kajimoto; Hiroaki Naraba; Naoharu Iwai
Journal:  RNA       Date:  2006-07-26       Impact factor: 4.942

10.  Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?

Authors:  Shali Mazaki-Tovi; Roberto Romero; Sun Kwon Kim; Edi Vaisbuch; Juan Pedro Kusanovic; Offer Erez; Tinnakorn Chaiworapongsa; Francesca Gotsch; Pooja Mittal; Chia-Ling Nhan-Chang; Nandor Gabor Than; Ricardo Gomez; Jyh Kae Nien; Samuel S Edwin; Percy Pacora; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.